Shortage of Levothyroxine after Japan earthquake resolved by Actavis

It has been announced that the shortage of Levothyroxine tablets in Japan after the March earthquake has been resolved when generic pharmaceuticals manufacturer Actavis was able to deliver 10 million tablets to Japan in record time.

ASKA Pharmaceutical Co., Ltd appealed for assistance from Actavis UK (the main location for the production of Levothyroxine tablets) on 14th March, after its plant was damaged as a result of the earthquake. By 16th March, Actavis had started sending documents to the Japanese government asking them to grant the product emergency registration, and then on the 18th, 10 million tablets were ready to be dispatched.

Twenty days after the initial request for the Levothyroxine tablets, they arrived in Tokyo – a record time for dispatching generic pharmaceuticals abroad.

Sara Vincent, UK-Actavis Managing Director, promised to “continue our support as required, until the ASKA site is back up and running”.

Actavis is one of the world’s leading players in the development, manufacture, and sale of first-class generic pharmaceuticals. The successful integration of a number of acquisitions has helped position Actavis amongst the world’s largest companies in the industry. Founded in 1956, the Group has more than 10,000 employees operating in over 40 countries around the globe.

ASKA Pharmaceutical Co., Ltd is a joint venture partner of Actavis.

To learn more about Actavis, visit www.actavis.com/en.